Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma

被引：2

作者：

Khattak, Muhammad A. ^{[1
]}

Bakr, Farrah ^{[1
]}

Krzystanek, Marcin ^{[2
]}

Szallasi, Zoltan ^{[2
,3
]}

Gerlinger, Marco ^{[4
]}

Santos, Claudio ^{[4
]}

Swanton, Charles ^{[4
]}

Pickering, Lisa M. ^{[1
]}

Gore, Martin E. ^{[1
]}

Larkin, James M. G. ^{[1
]}

机构：

[1] Royal Marsden Natl Hlth Serv Fdn Trust, London, England

[2] Tech Univ Denmark, DK-2800 Lyngby, Denmark

[3] Harvard Univ, Sch Med, Boston, MA USA

[4] Canc Res UK, London Res Inst, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 07期

基金：

英国医学研究理事会;

关键词：

ENDOTHELIAL GROWTH-FACTOR; HYPERTENSION; INHIBITOR; CANCER; EVEROLIMUS; SORAFENIB; SURVIVAL; CYTOKINE; RISK;

D O I：

10.1200/JCO.2012.46.9353

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：971 / 972

页数：3

共 15 条

[1] Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin [J].

Armstrong, Andrew J. ;

George, Daniel J. ;

Halabi, Susan .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) :3402-3407

[2]

Bhargava P, 2010, GEN CANC S SAN FRANC

[3] Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24 [J].

Goodwin, R. ;

Ding, K. ;

Seymour, L. ;

LeMaitre, A. ;

Arnold, A. ;

Shepherd, F. A. ;

Dediu, M. ;

Ciuleanu, T. ;

Fenton, D. ;

Zukin, M. ;

Walde, D. ;

Laberge, F. ;

Vincent, M. ;

Ellis, P. M. ;

Laurie, S. A. .

ANNALS OF ONCOLOGY, 2010, 21 (11) :2220-2226

[4] Rapid Development of Hypertension by Sorafenib: Toxicity or Target? [J].

Humphreys, Benjamin D. ;

Atkins, Michael B. .

CLINICAL CANCER RESEARCH, 2009, 15 (19) :5947-5949

[5] mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor [J].

Lane, Heidi A. ;

Wood, Jeanette M. ;

McSheehy, Paul M. J. ;

Allegrini, Peter R. ;

Boulay, Anne ;

Brueggen, Joseph ;

Littlewood-Evans, Amanda ;

Maira, Sauveur-Michel ;

Martiny-Baron, Georg ;

Schnell, Christian R. ;

Sini, Patrizia ;

O'Reilly, Terence .

CLINICAL CANCER RESEARCH, 2009, 15 (05) :1612-1622

[6]

Motzer R, 2012, EUR SOC MED ONC C VI

[7] Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors [J].

Motzer, Robert J. ;

Escudier, Bernard ;

Oudard, Stephane ;

Hutson, Thomas E. ;

Porta, Camillo ;

Bracarda, Sergio ;

Grunwald, Viktor ;

Thompson, John A. ;

Figlin, Robert A. ;

Hollaender, Norbert ;

Kay, Andrea ;

Ravaud, Alain .

CANCER, 2010, 116 (18) :4256-4265

[8]

Negrier S, 2007, CANCER-AM CANCER SOC, V110, P2468, DOI 10.1002/cncr.23056

[9] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma [J].

Patil, S. ;

Figlin, R. A. ;

Hutson, T. E. ;

Michaelson, M. D. ;

Negrier, S. ;

Kim, S. T. ;

Huang, X. ;

Motzer, R. J. .

ANNALS OF ONCOLOGY, 2011, 22 (02) :295-300

[10] Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib [J].

Rini, Brian I. ;

Cohen, Darrel P. ;

Lu, Dongrui R. ;

Chen, Isan ;

Hariharan, Subramanian ;

Gore, Martin E. ;

Figlin, Robert A. ;

Baum, Michael S. ;

Motzer, Robert J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (09) :763-773

← 1 2 →